These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 12496752)

  • 1. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.
    Rogers JF; Morrison AL; Nafziger AN; Jones CL; Rocci ML; Bertino JS
    Clin Pharmacol Ther; 2002 Dec; 72(6):711-7. PubMed ID: 12496752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.
    Ebert U; Oertel R; Kirch W
    Clin Pharmacol Ther; 2000 May; 67(5):538-48. PubMed ID: 10824633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.
    Kim JS; Nafziger AN; Tsunoda SM; Choo EE; Streetman DS; Kashuba AD; Kulawy RW; Beck DJ; Rocci ML; Wilkinson GR; Greenblatt DJ; Bertino JS
    J Clin Pharmacol; 2002 Apr; 42(4):376-82. PubMed ID: 11936561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
    Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of hormone replacement therapy on CYP3A activity.
    Gorski JC; Wang Z; Haehner-Daniels BD; Wrighton SA; Hall SD
    Clin Pharmacol Ther; 2000 Oct; 68(4):412-7. PubMed ID: 11061581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
    Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.
    Ma JD; Lawendy NM; Fullerton T; Snyder PJ; Nafziger AN; Bertino JS
    Int J Clin Pharmacol Ther; 2009 Feb; 47(2):111-9. PubMed ID: 19203567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
    Wermeling DP; Record KA; Archer SM; Rudy AC
    Epilepsy Res; 2009 Feb; 83(2-3):124-32. PubMed ID: 19046855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
    Prueksaritanont T; Vega JM; Rogers JD; Gagliano K; Greenberg HE; Gillen L; Brucker MJ; McLoughlin D; Wong PH; Waldman SA
    J Clin Pharmacol; 2000 Nov; 40(11):1274-9. PubMed ID: 11075313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.